Cite
MLA Citation
David Reardon et al.. “CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS.” Neuro-oncology, vol. 22, n.d., p. ii40. http://access.bl.uk/ark:/81055/vdc_100115126340.0x000005